Financial Performance - Total revenue increased by 2.2% to HKD 4,566 million, with HKD 3,671 million from the tissue segment and HKD 895 million from personal care[2] - Gross profit decreased by 12.9% to HKD 1,512 million, with a gross margin decline of 5.8 percentage points to 33.1%[2] - Operating profit fell by 36.5% to HKD 446 million, with an operating margin decrease of 5.9 percentage points to 9.8%[2] - EBITDA decreased by 22.7% to HKD 780 million, with an EBITDA margin of 17.1%[2] - Net profit decreased by 37.8% to HKD 344 million, with a net profit margin decline of 4.9 percentage points to 7.5%[2] - Exchange gains totaled HKD 11.8 million, up from HKD 4.8 million in the same quarter last year[2] Strategic Focus - The company aims to achieve sustainable profitable growth by focusing on brand building, product structure optimization, and efficient cost and financial management[2] - The company plans to actively respond to rising costs to further consolidate its market leadership[2] Operating Environment - The operating environment remains challenging due to ongoing COVID-19 uncertainties in China and Southeast Asia[2] Financial Reporting - The financial data presented is unaudited and may differ from the audited figures to be reported by the parent company, Essity[3] - Essity Aktiebolag (publ) holds approximately 51.59% of the issued share capital of the company[8] - Essity plans to publish its unaudited financial results for Q1 2022 on or around April 22, 2022[8] - The financial data for the three months ending March 31, 2022, has not been reviewed or audited by independent auditors, and may differ from the final audited figures[8]
维达国际(03331) - 2022 Q1 - 季度财报